Cargando…

Clofazimine in Nontuberculous Mycobacterial Infections: A Growing Niche

Infection secondary to rapidly growing mycobacteria (RGM) is associated with significant morbidity and mortality, especially in individuals with underlying structural lung disease or immune compromise. Such infections, particularly those caused by the Mycobacterium abscessus group, are challenging t...

Descripción completa

Detalles Bibliográficos
Autores principales: McGuffin, Sarah A, Pottinger, Paul S, Harnisch, James P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6124512/
https://www.ncbi.nlm.nih.gov/pubmed/30202770
http://dx.doi.org/10.1093/ofid/ofx147
Descripción
Sumario:Infection secondary to rapidly growing mycobacteria (RGM) is associated with significant morbidity and mortality, especially in individuals with underlying structural lung disease or immune compromise. Such infections, particularly those caused by the Mycobacterium abscessus group, are challenging to treat due to high virulence, antibiotic resistance, and the lack of effective and tolerable therapies. Although novel antimycobacterials are under development, clofazimine—a drug historically administered as part of multidrug therapy regimens for Mycobacterium leprae—holds promise as a chemotherapeutic for the treatment of RGM. The history, pharmacologic properties of clofazimine, as well as in vitro and in vivo studies against RGM are described here and highlight a potential new niche for an old drug.